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Abstract. The aim of the present study was to determine 
the molecular basis of the beneficial effects of genistein 
and/or menaquinone-4 (MK-4) on bone quality. Initially, 
1 µM genistein was applied to MC3T3-E1 cells for 24 h and 
the upregulated mRNAs that were detected by microarray 
were selected for further examination by reverse transcrip-
tion-quantitative-polymerase chain reaction. Among them, 
alterations were observed in the level of GATA-binding protein 
6 (GATA6), Notch gene homolog 2 (NOTCH2), Wnt family 
member 5A (WNT5A), bone γ-carboxyglutamate protein 
(BGLAP), chondroadherin (CHAD), dipeptidyl peptidase 4 
(DPP4), ectonucleotide pyrophosphatase/phosphodiesterase 
2 (ENPP2), alkaline phosphatase (ALP) 3 and ATPase 
phospholipid-transporting 11A (ATP11A) in response to 
treatment with 0.1 µM 17-β-estradiol, 1 µM genistein, and/or 
1 µM MK-4. GATA6, NOTCH2 and WNT5A are considered 
to be associated with osteoclast, but not osteoblast, function; 
however, increases in osteoblastic mRNAs, including BGLAP 
and CHAD, were observed in each of the treatment groups 
at 48 h. Immunocytochemical analysis confirmed an increase 
in CHAD and DPP4 proteins following the administration 
of genistein + MK-4. Furthermore, genistein + MK-4 led to 
alterations in cell morphology to spindle or oval shapes, and 
increased the intensity of ALP staining. Although the level of 
ALP mRNA was not consistently altered in response to the 
treatments, a marked increase in ALP activity was observed 
following 96 h treatment with genistein + MK-4. Therefore, 
the simultaneous intake of genistein and MK-4 appears to be 
beneficial for the maintenance of bone quality.
Introduction
Bone is a basic component of the musculoskeletal system and 
is constantly remodeled by the function of osteoblasts and 
osteoclasts (1-3). This bone remodeling is maintained in men 
throughout life, whereas following menopause, women exhibit 
accelerated bone loss due to a decrease in estrogen levels, 
leading to osteoporosis (4). Osteoporosis is a serious social and 
health problem in a progressively aging society, and the associ-
ated increases in medical expenditure have become a serious 
problem in developed and developing countries (5). Various 
epidemiological studies have demonstrated that the intake of 
various vitamins and phytoestrogens can act to support the 
enrichment of bone mineral density (BMD) (6). Therefore, 
utilization of food-based nutrients is considered to be the most 
economical and simple way to prevent bone loss. For example, 
genistein, which has a similar structure to estrogen, has been 
demonstrated to aid in maintaining BMD (6-9). Furthermore, 
the simultaneous intake of genistein and menaquinone-7 
(MK-7), a major form of vitamin K2, is considered to be more 
effective for the maintenance of BMD (10-12). However, 
MK-7 is only present in fermented foods. For example, the 
traditional Japanese food, Nattō, a type of fermented soybean, 
is considered to be beneficial; however, due to its peculiar 
smell, its intake is not always common, even in Japan (10), and 
non‑Japanese experience difficulty with its intake.
In addition to the extremely high concentration of MK-7 in 
Nattō (13), another major form of vitamin K2, menaquinone-4 
(MK-4) is found in meat, eggs and dairy foods; however, its 
concentration is often low (14,15). In addition, the bioavail-
ability of MK-4 is unclear (16).
In the present study, the effects of genistein and/or MK-4 
at dietary obtainable concentrations on the level of mRNAs 
and their protein products in MC3T3-E1 cells derived from 
neonatal mouse calvaria were evaluated.
Materials and methods
Reagents. Fetal bovine serum (FBS), and phenol red-free 
Eagle's minimal essential medium, α‑modification (α-MEM), 
were obtained from Thermo Fisher Scientific, Inc. (Osaka, 
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Japan). Genistein, 17-β-estradiol and MK-4 were purchased 
from Sigma-Aldrich; Merck KGaA (Darmstadt, Germany), 
and dissolved in ethanol (Nacalai Tesque, Inc., Kyoto, Japan).
MC3T3‑E1 cell culture, treatment and RNA preparation. 
Osteoblastic MC3T3-E1 cells derived from the calvaria of a 
newborn C57BL/6 mouse were obtained from the Riken Cell 
Bank (Tokyo, Japan) and used at passages 3-5. The cells were 
maintained in α-MEM containing 10% (v/v) FBS. All cells 
were plated at a density of 1x105 cells in 10-cm culture dishes, 
and incubated at 37˚C in a humidified atmosphere containing 
5% CO2. When subconfluent, the cells were subcultured into 
35-mm dishes at a density of 1x105 cells and then cultured 
with the media containing 0.1% ethanol (control), 0.1 µM 
17-β-estradiol, 1 µM genistein, 1 µM MK-4, 17-β-estradiol + 
genistein (0.1 µM + 1 µM), 17-β-estradiol + MK-4 (0.1 µM + 
1 µM) or genistein + MK-4 (1 µM + 1 µM) for 24, 48 or 
96 h. The total RNA was extracted from 24 and 48 h cell 
cultures using ISOGEN reagent (Nippon Gene Co., Ltd., 
Tokyo, Japan). All total RNA samples were quality checked by 
RNA Pico Chips using an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Inc., Santa Clara, CA, USA), and treated with 
RNase-free DNase I recombinant (Roche Diagnostics GmbH, 
Mannheim, Germany) to isolate DNA-free RNA.
Identification of mRNA species upregulated by genistein. From 
each 24 h culture with or without 1 µM genistein, 1 mg total 
RNA was obtained. Oligo-dT (Sigma-Aldrich; Merck KGaA) 
purification was performed as previously described (17). 
Following this, polyA + RNA was compared using a mouse GE 
microarray version 2.0 (Agilent Technologies, Inc.). Among the 
mRNAs that were observed to increase by >3 times following 
treatment with genistein, 19 mRNAs with known functions 
(Table I) were subjected to reverse transcription-quantitative 
polymerase chain reaction (RT‑qPCR) in order to confirm the 
effects of 17-β-estradiol, genistein, MK-4, 17-β-estradiol + 
MK-4 and genistein + MK-4 at 24 and 48 h.
Quantification of mRNAs using RT‑qPCR. From ~40 ng of 
total RNA, first‑strand cDNA was synthesized using ReverTra 
Ace® reverse transcriptase (Toyobo, Co., Ltd., Osaka, Japan) 
with 5 pmol oligo-dT primers in a 20 µl reaction mixture, as 
indicated in the manufacturer's instructions, at 50˚C for 1.5 h. 
RT-qPCR was performed using the Stratagene Mx3000P 
qPCR System (Agilent Technologies, Inc.). The reaction 
mixture consisted of a final volume of 20 µl containing 
1 µl of cDNA sample, 5 pmol of a set of gene-specific 
primers designed using Primer-3-Plus (http://primer3plus.
com; Table I), and 10 µl of Brilliant III Ultra-Fast SYBR 
Green QPCR Master Mix (Agilent Technologies, Inc.). The 
cycling conditions included a denaturing step at 95˚C for 
2 min, followed by 60 cycles at 95˚C for 5 sec and 60˚C for 
20 sec. The number of cycles of amplification required to 
reach the threshold (quantification cycle; Cq) were obtained 
using an amplification plot and the threshold line automati-
cally reported. To determine the number of copies of the 
targeted mRNAs in the samples, the Cq values of the genes 
were normalized against that of β-actin using the 2-ΔΔCq 
method (18). RT-qPCR products were run on 1% agarose gels 
and were confirmed as a single band.
Immunocytochemistry of chondroadherin (CHAD), dipep‑
tidylpeptidase 4 (DPP4/CD26) and alkaline phosphatase 
(ALP). The protein expression levels of CHAD and DPP4 
were immunocytochemically examined, with anti-ALP used 
as an MC3T3-E1 cell marker. The cells were seeded into BD 
Bio-Coat Collagen IV Cellware plates (Cosmo Bio Co., Ltd., 
Tokyo, Japan) at a density of 1x105 cells/well, and incubated 
with 17-β-estradiol, genistein, MK-4, 17-β-estradiol + MK-4 
or genistein + MK-4 for 48 or 96 h. The cells were fixed 
with 4% (w/v) paraformaldehyde in TBS for 30 min at room 
temperature. Subsequently, the cells were washed three times 
with 200 µl TBS and incubated in blocking solution containing 
1% bovine serum albumin (Sigma-Aldrich; Merck KGaA) and 
0.1% Tween-20 in TBS for 1 h at room temperature. Following a 
further wash with TBS, the fixed cells were incubated overnight 
at 37˚C with a goat polyclonal anti‑ALP antibody (5 µg/ml; 
cat. no. AF2910; R&D Systems, Inc., Minneapolis, MN, USA), 
rabbit polyclonal anti-CHAD antibody (dilution, 1:500; cat. 
no. NBP1-87031, Novus Biologicals, LLC, Littleton, CO, USA) 
and a rabbit polyclonal anti-DPP4 antibody (dilution, 1:500; cat. 
no. sc-9153, Santa Cruz Biotechnology, Inc., Dallas, TX, USA). 
The cells in each well were then washed three times with TBS, 
and incubated with fluorescein isothiocyanate-conjugated 
anti-goat and tetramethylrhodamine-conjugated anti-rabbit 
secondary antibodies (dilution, 1:800; cat. nos. T6778 and 
F7367, respectively; Sigma-Aldrich; Merck KGaA) for 1 h at 
room temperature. The cells were incubated with DAPI (Cell 
Signaling Technology, Inc., Danvers, MA, USA) for nuclear 
staining and were viewed under a BZ-8000 All-in-One 
Fluorescence Microscope (Keyence Corporation, Osaka, 
Japan).
Measurement of ALP activity. The activity of ALP was measured 
in 1x105 MC3T3-E1 cells in 12-well culture plates after 96 h of 
treatment. The cells were fixed with 4% (w/v) paraformalde-
hyde in TBS for 30 min at room temperature and washed three 
times in TBS. The activity of ALP was measured by adding 
0.25 mg/ml naphthol AS-BI phosphate (Sigma-Aldrich; Merck 
KGaA) for 1 h. Following a wash with TBS, ALP activity levels 
were measured via image capture using a Canon IXY 50S 
camera (Canon Inc., Tokyo, Japan) and intensity measurement 
using Adobe Photoshop version-20160113.r.355 x64 (Adobe 
Systems, Inc., San Jose, CA, USA).
Statistical analysis. All values are presented as the 
mean ± standard deviation. In order to compare the differences 
between the control and treatment groups, all groups were 
compared using one-way analysis of variance with Tukey's 
honest significant difference applied as a post hoc test (19). 
Statistically significant differences are indicated in each table. 
Analyses were performed using SPSS software (version 19; 
IBM SPSS, Armonk, NY, USA). P<0.05 was considered to 
indicate a statistically significant difference.
Results
The half-maximal inhibitory concentration of genistein against 
17-β-estradiol is reportedly 145 nM for estrogen receptor α 
and 8.4 nM for estrogen receptor β, and the two receptors are 
almost completely occupied by genistein at concentrations of 
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1-10 µM (20). Thus, the effects of 0.1-100 µM of genistein on 
MC3T3-E1 cell growth were examined (Fig. 1). This revealed 
that 100 µM genistein inhibited cell growth at 24 and 98 h. 
Thus, in order to select mRNAs that may be involved in modi-
fying osteoblastic function, mRNAs from cells treated with 
and without 1 µM of genistein were compared using microarray 
analysis at 24 h. Among the mRNAs from genistein-treated 
cells, almost 13,000 spots were revealed to exhibit a >3 fold 
higher signal compared with mRNAs from cells not treated 
with genistein. Of these, the mRNAs without any known func-
tion were removed, and those potentially affecting osteoblastic 
function (Table I) were selected and subjected to RT-qPCR in 
order to confirm their level of expression in cultures treated 
with 17-β-estradiol, genistein, MK-4, 17-β-estradiol + MK-4 
or genistein + MK-4 for 24 or 48 h.
Among the identified factors, no significant differ-
ence was observed for Wnt family member 3A (WNT3A; 
Table II). At 24 h, all treated groups tended to exhibit 
increased GATA-binding protein 6 (GATA6) mRNA levels 
compared with the control; however, these differences were 
not significant. This effect was also observed at 48 h, and the 
GATA6 level was significantly increased genistein-treated 
cells compared with the other treatment groups at 48 h. At 
48 h, the levels of NOTCH2 and WNT5A in the genistein 
treatment groups tended to be higher compared with those of 
other groups, without statistical significance. NOTCH2 in the 
MK‑4 treatment group was significantly lower than that in the 
genistein treatment group (P=0.0475).
Figure 1. Proliferation of MC3T3-E1 cells with or without genistein. Values 
are presented as the mean ± standard deviation.
Table I. mRNAs with expression increased >3 fold in the microarray assay following 24 h treatment with 1 µM genistein were 
subjected to reverse transcription-quantitative polymerase chain reaction to validate the expression level change.
 Primer sequence
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Accession no. Gene name (genetic symbol) Forward Reverse
NM_007432 Alkaline phosphatase 3, intestine,  agaagctgcaataccacaac atttggttgctgttggaact
 not Mn requiring (ALP3)
NM_015804 ATPase, class VI, type 11A (ATP11A) gacttgtgggtgtgtcgatg ggaagagaactgggtggaca
NM_007541 Bone γ carboxyglutamate protein (BGLAP)  gggcagagagagaggacagg acctgtgctgccctaaagc
NM_007557 Bone morphogenetic protein 7 (BMP7) atggtggtatcgagggtgga tctcctacccctacaaggcc
NM_013878 Calcium binding protein 2 (CABP2) ggacccatcagctccacaaa ccaggagtttgaccgagacc
NM_007689 Chondroadherin (CHAD) tggataatgggagggaacg aaatccccgaccaagaggt
NM_010074 Dipeptidylpeptidase 4 (DPP4) gttctggggacaggcatc ccagcacatctattcccaca
NM_015744 Ectonucleotide pyrophosphatase/ gcaggtatgtcttgagggtca ctcgggtgagggacatcg
 phosphodiesterase 2 (ENPP2)
NM_010258 GATA binding protein 6 (GATA6) gcatttttgctgccatctg aaccccgagaacagtgacc
NM_008398 Integrin α 7 (ITGA7) cagatcgcatggcactttcg atcctcagcacctctgggat
M21041 Microtubule-associated protein 2 (MAP2) accaggatgccagatttggg accttcctccatcctccctc
NM_144557 Myosin VIIA and Rab interacting protein ttcttcaggaccttggcact agagctgctgctcctaccag
 (MYRIP)
BC059256 Notch gene homolog 2 (NOTCH2) agagagcgagggaagatgga gagcacccatacctgacacc
NM_172766 Nuclear factor related to κ B binding cccttggagaccctgctaag aaagcctcctggtcccttg
 protein (NFRKB)
NM_008873 Plasminogen activator, urokinase (PLAU) gtgttggcctttcctcggta gtggcagtgtacttggagct 
NM_173413 RAB8B, member RAS oncogene family ccacaggaatgaacgacca gagagcaacgagcatttgtttt
 (RAB8B), mRNA
NM_009446 Tubulin, α 3 (TUBA3) cgtggtattgctcagcatgc agtttgccatctacccagcc
NM_009521 Wingless-related MMTV integration site 3A ggtgtttctccaccaccatc cgctcagctatgaacaagca
 (WNT3A)
NM_009524 Wingless-related MMTV integration site 5A ccaaacagctgcaacacctc cagaaccagccacttagggg
 (WNT5A)
NM_007431 Alkaline phosphatase, liver/bone/kidney ctacgcaccctgttctgagg ggcgtccatgagcagaacta
 (ALPL)
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The levels of bone γ-carboxyglutamate (BGLAP) mRNA 
in all treatment groups, with the exception of genistein at 24 h, 
were increased compared with the control group, whether 
significant or not; the increase following genistein treatment 
at 48 h was statistically significant (Table III). 17-β-estradiol 
appeared to increase bone morphogenetic protein 7 (BMP7) 
mRNA at 48 h, although this difference was not significant 
compared with the 48 h control group. The levels of CHAD 
and DPP4 in all of the treatment groups at 48 h were higher 
compared with those of the control; however, a significant 
difference was observed only in the genistein treatment group. 
Similarly, the levels of ectonucleotide pyrophosphatase/phos-
phodiesterase 2 (ENPP2) mRNA tended to be increased 
following the treatments, however a significant difference 
was obtained only in the genistein treatment group at 48 h. 
A significant increase in ATPase phospholipid‑transporting 
11A (ATP11A) mRNA was observed following treatment with 
genistein + MK-4 for 48 h compared with the other groups. 
Differences in the expression levels of the following mRNAs 
were not observed between the treatment and control groups: 
Calcium-binding protein 2 (CABP2); nuclear factor related to 
κB-binding protein (NFRKB); integrin subunit α 7 (ITGA7); 
microtubule-associated protein 2 (MAP2); plasminogen-acti-
vator, urokinase (PLAU); RAB8B, member RAS oncogene 
family; and tubulin α 3 (TUBA3).
Alterations in CHAD and DPP4 mRNA levels were similar 
to each other (Table III). As these encode cell membrane-bound 
proteins that are suitable for quantitative analysis, the changes 
in their protein products were examined immunocytochemi-
cally (Fig. 2). At 48 h, an effect of 17-β-estradiol on CHAD or 
DPP4 was not always apparent. Genistein treatment induced 
the appearance of small fluorescent foci for CHAD and 
DPP4 along with alterations in cell morphology into oval or 
spindle-shape following 48 h treatment; such an effect was not 
always observed following MK-4 treatment. However, treat-
ment with 17-β-estradiol + MK-4 induced the appearance of 
granular and diffuse CHAD and DPP4 staining, which were 
also apparent in the genistein + MK-4 group. After 96 h, 
alterations in the cell shape were marked in the MK-4 treat-
ment cultures, which exhibited high intensities of CHAD and 
DPP4 staining. The small foci had disappeared, and larger 
spots along with diffuse staining appeared. These alterations 
were the most marked in Genistein + MK-4-treated cells.
A significant increase in ALP activity was observed only 
in the 96 h genistein + MK-4 treatment group compared with 
the other groups (Table IV). ALP3 mRNA was significantly 
increased in the 48 h genistein treatment compared with 
all other treatment and control groups (Table III), whereas 
alkaline phosphatase liver/bone/kidney mRNA exhibited no 
differences in expression in any of the treatment groups (data 
not shown).
Discussion
Among the Japanese population, the daily intake of genistein is 
reported to be ~12 mg (50 µmol) from 80 g of soy products (21), 
and people in eastern Japan typically consume 50 g of Nattō 
each day, supplying 3-5 mg of MK-7 (~6 µmol) simultane-
ously (22). Pre‑menopause, Nattō intake is useful to promote 
bone formation (11). By contrast, MK-4 is contained in daily 
foods like meat, eggs and dairy foods, and can be consumed 
daily, but its concentrations are low at 1-10 nmol/100 g, thus, 
MK-4 intake is very limited (15). In the present study, in 
order to elucidate the utility of MK-4, mRNAs that exhib-
ited altered levels in response to genistein treatment were 
identified initially in MC3T3-E1 cells using a microarray. 
However, microarrays are not always useful for quantitative 
analysis. Therefore, to validate the effect of genistein and/or 
Table II. Effects of 17-β-estradiol, genistein and/or MK-4 on mRNA levels of GATA6, NOTCH2 and WNT5A.
 GATA6 NOTCH2 WNT5A
 ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑ ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑
Treatment Expression P-valuea Expression P-valuea Expression P-valuea
24 h      
  Control  0.01±0.01 0.0018 0.12±0.14 0.049 0.33±0.46 0.0489
  17-β-estradiol 10.92±6.05  2.45±1.40  3.37±5.10 
  Genistein 1.53±2.83 0.0018 0.54±0.79  0.60±1.11 
  MK-4  3.01±3.08  0.0066 0.04±0.10 0.0281 1.44±2.15 
  17-β-estradiol+MK-4 12.60±29.74  0.45±0.26  0.27±0.36 0.0469
  Genistein+MK-4 11.26±8.15  0.67±0.84  3.06±5.49 
48 h
  Control  0.75±0.73 0.0012 1.64±1.32  2.56±2.38 
  17-β-estradiol 5.36±6.67  0.0097 3.09±4.66  6.94±9.09 
  Genistein  34.20±27.60  5.58±6.61  13.16±17.21 
  MK-4 4.18±3.35 0.0058 0.33±0.38 0.0475 3.58±3.29 
  17-β-estradiol+MK-4 3.11±2.38 0.0037 2.01±1.24  3.71±3.15 
  Genistein+MK-4  2.14±1.82 0.0024 3.06±3.30  5.68±4.38
Values are presented as the mean ± standard deviation of 5-6 samples and expressed as 10-3x β-actin expression. aP-value vs. genistein 48 h group (one-way 
analysis of variance with Tukey's honest significant difference test as a post hoc test). No significant difference in the expression of WNT3A was confirmed 
among any of the groups. GATA6, GATA binding protein 6; NOTCH2, Notch gene homolog 2; WNT5A, Wnt family member 5A; MK-4, menaquinone-4.
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MK-4 on selected mRNAs, in comparison with the effects of 
17-β-estradiol, RT-qPCR was also performed.
Although the mRNAs were selected because genistein 
increased their levels by >3 fold compared with the control 
at 24 h, this effect could not be confirmed in certain mRNAs. 
Genistein is a phytoestrogens that exerts similar effects to 
17-β-estradiol, although these effects are not always identical. 
For example, at 48 h, a significant increase in GATA6 mRNA 
was observed following genistein treatment, but not following 
17-β-estradiol treatment. However, the 17-β-estradiol + MK-4 
and genistein + MK-4 maintained the expression level of 
GATA6 at a level consistent with that of the control group. As 
GATA6 is reported to suppress bone differentiation (23), the 
administration of estrogenic substances together with MK-4 
appears to be beneficial for bone formation.
Osteoclastogenesis and bone resorption are inhibited 
by NOTCH1 and enhanced by NOTCH2 (24). In mouse 
embryonic stem cells, recombinant WNT5A has been reported 
to significantly enhance osteogenic yield, while recombinant 
WNT3A or other positive regulators of β-catenin decrease the 
expression of osteogenic markers (25). However, WNT5A is 
usually considered to promote osteoclast differentiation and 
prevent adipocyte differentiation (26). Genistein alone (27) 
and MK-4 alone (28,29) reportedly promote bone forma-
tion; however, in the current study, their co-administration 
appeared to be more beneficial as it allowed the maintenance 
of NOTCH2 and WNT5A mRNAs at the levels observed in 
the control cells.
In the current study, genistein and/or MK-4 treatments 
were shown to increase BGLAP, also known as osteocalcin, 
indicating that this promoted an osteoblastic phenotype in the 
MC3T3-E1 cells. In fact, cell morphology was altered following 
96 h treatments, also exhibiting a high intensity of ALP. The 
increase of BMP7 by 17-β‑estradiol also indicated beneficial 
Figure 2. Immunocytochemical analysis of CHAD and DPP4 proteins in control cells and cells treated with 17-β-estradiol, genistein, MK-4, 17-β-estradiol + 
MK-4 or genistein + MK-4 for 48 and 96 h. Left panel, anti-CHAD or anti-DPP4 staining; center panel, anti-ALP staining; and right panel, merge with DAPI 
staining. Scale bar, 100 µm. MK-4, menaquinone-4; CHAD, chondroadherin; DPP4, pipeptidylpeptidase 4; ALP, alkaline phosphatase.
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effect of estrogenic stimulation on osteoblastic activity. The 
background of high activity of ALP by genistein + MK-4 was 
not always obvious.
Significant increases in the mRNA level of CHAD by 
MK-4 treatment were not consistently observed within 48 h, 
whereas strong expression of its protein was clearly visible 
by immunocytochemistry. CHAD has been reported to 
reduce preosteoclast motility and bone resorption without 
affecting osteoblast parameters, including the expression of 
runt related transcription factor 2 and BGLAP, the activity of 
ALP and bone formation (30). Therefore, the findings of the 
current study indicated a beneficial effect on bone formation 
in response to genistein + MK-4 treatment. However, the 
expression of DPP4 does not always appear to be beneficial 
for bone formation (31). Type 2 diabetes is associated with an 
increased risk of fracture. Incretins (gastric inhibitory poly-
peptide, glucagon like peptide 1, and 2) have an important 
role in the regulation of bone turnover and insulin release, 
and are digested by DPP4 (31). Therefore, DPP4 inhibitors 
appear to be useful for patients with type 2 diabetes, to 
ameliorate diabetes and also to prevent bone fracture. DPP4 
is potentially induced by genistein and/or MK-4, of which 
intake is inevitable in healthy people via daily food consump-
tion; however the concentrations obtained from food tend to 
be low.
ENPP2 encodes a secreted protein (32), which is therefore 
unsuitable for immunocytochemical analysis and was not 
assessed in the current study. Acidosis increases the mRNA 
levels of ENPPs and potentially contributes to decreased 
mineralization. However, among these ENPP proteins, the level 
of ENPP2 is not high in osteoblasts (33). ATP11A likely drives 
the transport of ions, such as calcium, across membranes (34); 
therefore, its increase by genistein + MK-4 treatment may be 
beneficial for the maintenance of bone.
In summary, the results of the present study suggest that 
the administration of genistein and/or MK‑4 may be benefi-
cial to maintain and/or improve BMD and bone metabolism. 
Compared with MK-7, the dietary intake of MK-4 is more 
common, despite its low concentration in foods. The simul-
taneous administration of MK-4 and genistein appears to 
have a substantial beneficial effect; thus, the consumption of 
beans with meat, eggs and dairy foods is advisable to increase 
osteoblastic activity.
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